SynthesisSkeletal radiology2017
F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature.
Synthesis in Skeletal radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- The utility ofJournal of orthopaedic surgery and research · 2020Pooled it
- Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020Pooled it
- Review
- Current Position of Nuclear Medicine Imaging in Primary Bone Tumors.Diagnostics (Basel, Switzerland) · 2025Review
- Advances in the Molecular Imaging of Sarcoma: An Emphasis on Metabolic Imaging.Molecular imaging and biology · 2025Review
- Incidental Hibernoma With an Atypical Presentation: Diagnostic Approach, Pathologic Correlation, and Lessons Learned.Cureus · 2025Article
- The role of positron emission tomography in the evaluation and management of musculoskeletal lesions-a narrative review.Annals of joint · 2025Review
- Musculoskeletal Pitfalls on Molecular Imaging Studies of Oncologic Patients: How to Stay Out of Trouble.Tomography (Ann Arbor, Mich.) · 2024Review
- Chondroma Arising from the Temporomandibular Joint: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.Cancers · 2022Review
- MRI features of low-grade and high-grade chondrosarcoma in enchondromatosis.Skeletal radiology · 2021Article
- A Radiological Scoring System for Differentiation between Enchondroma and Chondrosarcoma.Cancers · 2021Article
- Review
- Imaging features of cartilaginous tumors of the head and neck.Journal of clinical imaging science · 2021Review
- Article
- CORR Insights®: Does PET/CT Aid in Detecting Primary Carcinoma in Patients with Skeletal Metastases of Unknown Primary?Clinical orthopaedics and related research · 2020Article
- Solitary enchondromas-diagnosis and surveillance : Danish guidelines.Der Radiologe · 2020Review
- Chondrosarcomas in children and adolescents.EFORT open reviews · 2020Article
- Whole-body MRI in assessing malignant transformation in multiple hereditary exostoses and enchondromatosis: audit results and literature review.Skeletal radiology · 2020Review
- Diagnostic accuracy of functional imaging modalities for chondrosarcoma: A systematic review and meta-analysis.Journal of bone oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiscriminating among benign chondroid tumors, low-grade chondrosarcomas, and grade 2/3 chondrosarcomas is frequently difficult with standard imaging modalities. We systematically reviewed the literature to determine the performance of PET-CT in making this distinction.
methodsA systematic review was performed identifying 811 PubMed- and Embase-indexed articles containing combinations of "chondrosarcoma," "enchondroma," "chondroid," "cartilage" and "PET/CT," "PET," "positron." Eight articles including 166 lesions were included. Age, gender, tumor size, histologic grade, and SUVmax values were extracted for individual lesions when possible and otherwise recorded as aggregated data. Comparisons in SUVmax among benign, low-grade, and intermediate-/high-grade chondroid neoplasms were made.
resultsIndividual SUVs were available for 101 lesions; 65 additional lesions were reported as aggregated data. There were 101 malignant and 65 benign tumors. Benign tumors were seen more frequently in females (p = 0.04, Fischer's exact test), but malignancy was not associated with age or lesion size. SUVmax was lower for benign (1.6 ± 0.7) than malignant tumors (4.4 ± 2.5) (p < 0.0001, t-test). SUVmax was lower for grade 0/1 (2.0 ± 0.7) than grade 2/3 (6.0 ± 3.2) (p < 0.0001, t-test). Increasing SUVmax correlated with higher grade chondroid tumors (Spearman's rank, ρ = 0.78). SUVmax ≥4.4 was 99% specific for grade 2/3 chondrosarcoma.
conclusionsSUVmax correlates with histologic grade in intraosseous chondroid neoplasms; very low SUVmax supports a diagnosis of benign tumor, while elevated SUVmax is suggestive of higher grade chondrosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.